Rohto Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2021. The company expects net sales of JPY 183,000 million, operating income of JPY 21,800 million, and profit attributable to owners of parent of JPY 14,000 million or JPY 122.73 per share.